+7.3% for Injective — Overbought signals emerge amid surging volumes

Traders Union
All News
Crypto
Injective jumps 7.3% to $5.48 today

Highlights

Injective integrated Chainlink Data Streams, enabling decentralized applications to access real-world price feeds and expanding its product and developer ecosystem.
Over 6 million INJ tokens have been removed from circulation via community-driven buybacks and burns, reducing supply from the fixed 100 million total.
Trading volumes and daily user activity on Injective reached all-time highs as new on-chain markets launched, offering up to 5x leveraged asset exposure.

Record user activity and token burns as new features attract inflows

Injective has expanded its product offerings and developer environment following the integration of Chainlink Data Streams, which brings real-world price feeds to its decentralized applications. The protocol has also completed community-driven buybacks and token burns, removing over 6 million INJ from circulation out of the fixed 100 million supply, and has launched new on-chain markets enabling up to 5x leveraged exposure to select assets. Trading volumes and daily user activity have reached new highs, supported by rising developer engagement.

Mixed momentum and overbought signals as resistance levels tested

Technically, D1 Ichimoku Kijun at $4.98 now serves as the nearest dynamic support, while the MA-50 near $5.29 and the round $5.50 level act as immediate resistance. Momentum indicators are mixed — MACD and ADX show underlying weakness, but RSI remains supportive at 58.35. Both Stoch RSI and CCI indicate overbought conditions, suggesting the recent rally may have stretched short-term upside. BBP stands firmly positive at 0.63, pointing to strong buyer activity, while the Awesome Oscillator is neutral and does not reinforce the current trend. Price action is volatile, trading near the upper end of today’s $5.32 – $5.46 range, signaling pronounced intraday strength but also a divergence between short-term momentum and overbought oscillators, warranting caution.

Limited breakout risk as consolidation likely amid opposing trends

For the coming five trading days, INJ is expected to fluctuate within a typical volatility band between $5.43 and $5.48, reflecting prevailing conditions. The likelihood of a further breakout above the current range is low (below 20%), suggesting that sideways or downward moves are more probable as bullish intraday signals confront longer-term bearish trends. In the base scenario, INJ consolidates between dynamic support at $4.98 and resistance at $5.50. A confirmed move above $5.50 may trigger new bullish momentum, while a close below $4.98 could prompt deeper declines should sellers regain control.

Viktoras Karapetjanc, analyst at Traders Union, sees Injective showing strong short-term momentum driven by impressive user and developer activity. He notes that the recent product expansion and token burn have reinforced positive sentiment on fundamentals. Still, technical indicators highlight overbought conditions and the possibility of sideways or downward price action. A sustained move above $5.50 could spark further gains, but consolidation appears more likely for now. "With solid fundamentals and active community engagement, the odds favor a constructive outlook — I would accumulate selectively on dips above $4.98 while watching for a breakout confirmation near $5.50."

Previously it was reported that Injective is showing renewed short-term momentum above its 20-day moving average but remains constrained by resistance at the 50-day and long-term moving averages, with immediate support from the Ichimoku Kijun and overhead resistance capping upside. Mixed daily momentum—overbought stochastic readings, neutral-bullish RSI, and a bearish MACD—with strong ADX trend strength points toward continued sideways consolidation within a defined range, as intraday buying pressure has yet to overcome broader bearish signals.

Source of Data: INJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.